Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and Bristol Myers Squibb developed for ...